Skip to main content

Table 3 Mean volumes of care and total direct costs in euros per patient per period in the treat-to-target (T2T) and usual care (UC) groups after two and three years of follow-up

From: Treating to the target of remission in early rheumatoid arthritis is cost-effective: results of the DREAM registry

 

0-2 year

 

T2T (n=261)

UC (n=213)

 

UC from 2006 (n=69)

 
 

Volume

Costs

Volume

Costs

Difference in costs

Volume

Costs

Difference in costs

Consultations rheumatologist

10.4 ± 3.0

696 ± 199

10.3 ± 2.9

689 ± 195

7

10.2 ± 3.6

683 ± 239

13

Consultations nurse

8.8 ± 3.0

588 ± 200

7.8 ± 1.9†

522 ± 127†

66

6.6 ± 2.0†

438 ± 134†

150

Telephonic consultations

1.3 ± 1.8

34 ± 46

0.6 ± 1.4†

16 ± 36†

18

1.1 ± 1.9

29 ± 48

5

Hospital admissions

0.4 ± 2.7

178 ± 1,208

1.1 ± 4.2†

521 ± 1,901†

-343

0.3 ± 1.6

158 ± 714

20

Medication

        

 DMARDs/other

 

174 ± 165

 

249 ± 340

-75

 

166 ± 119

8

 Anti-TNF

 

3,121 ± 7,162

 

1,730 ± 4,905†

1,391

 

1,877 ± 5,086

1244

Total

 

4,791 ± 7,436

 

3,727 ± 5,773

1,064 (1,026 to 1,121)‡

 

3,351 ± 5,179†

1440 (1,387 to 1479)‡

 

0-3 year

 

T2T (n=127)

UC (n=180)

 

UC from 2006 (n=45)

 
 

Volume

Costs

Volume

Costs

Difference in costs

Volume

Costs

Difference in costs

Consultations rheumatologist

13.7 ± 3.3

917 ± 220

13.6 ± 3.3

909 ± 224

8

12.5 ± 3.8

838 ± 253†

79

Consultations nurse

12.1 ± 3.6

809 ± 244

8.9 ± 1.7†

596 ± 117†

213

8.4 ± 2.2†

565 ± 145†

244

Telephonic consultations

1.9 ± 2.1

49 ± 54

0.8 ± 1.7†

21 ± 45†

28

1.7 ± 2.5

43 ± 64

6

Hospital admissions

0.5 ± 3.2

215 ± 1,441

1.6 ± 5.0†

748 ± 2,263†

-533

0.8 ± 2.7

364 ± 1,217

-149

Medication

        

 DMARDs/other

 

260 ± 335

 

423 ± 612†

-163

 

259 ± 174

1

 Anti-TNF

 

4,160 ± 10,685

 

4,175 ± 10,070

-15

 

5,488 ± 11,528

-1,328

Total

 

6,410 ± 10,845

 

6,872 ± 11,033

-462 (-513 to -350)‡

 

7,558 ± 11,649

-1,148 (-1241 to -1075)‡

  1. Volumes are the mean ± standard deviation (SD).
  2. Anti-TNF, anti-tumour necrosis factor; CI, confidence interval; DMARDs, disease-modifying antirheumatic drugs.
  3. † P < 0.05 for differences between groups (T2T versus UC). ‡ 95% confidence interval bootstrapped.